CytomX Therapeutics(CTMX)
SOUTH SAN FRANCISCO, CABiotechnology
Focus: CytomX Therapeutics is a clinical-stage oncology biotech focused on protease-activated antibodies ('Probodies'), a proprietary platform technology designed to improve therapeutic selectivity in solid tumors. The company is publicly traded (NASDAQ: CTMX) and operates at the mid-cap biotech scale with growing revenue.
Profile data last refreshed 12h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
0
About CytomX Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow CytomX Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from CytomX Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
9 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$138M
Pipeline & Clinical Trials
CX-904
Solid TumorsClinical Trials (1)
NCT05387265A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors
Phase 1Help build intelligence for CytomX Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.